Clinical trial · Observational
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma
NCT03165409CI-TRIAL-00029783completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ipilimumab | Biological | Ipilimumab | ALIAS |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with less frequent general outpatient visits
- timeFrame
- Approximately 5 years
- measure
- Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with more frequent general outpatient visits
- timeFrame
- Approximately 5 years
- measure
- Treatment-related and all-cause AE costs for nivolumab/ipilimumab combination therapy for metastatic melanoma
- timeFrame
- Approximately 5 years
- measure
- Treatment-related and all-cause AE costs for nivolumab monotherapy for metastatic melanoma
- timeFrame
- Approximately 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with metastatic melanoma * Initiated at least 1 treatment for metastatic melanoma after 2011 * Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date * Patients who received at least 1 dose of study drug in CA209-067
References
Publications (0)
Data not yet available
No reference posted for this study.